Ziarco Pharma
Develops therapeutic agents for treating inflammatory and allergic diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD180—270m (Dealroom.co estimates Nov 2014.)
Dover England (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $7.6m | Series A | |
N/A | - | ||
£1.7m | Grant | ||
$33.0m | Series B | ||
N/A | Acquisition | ||
| Total Funding | CAD58.4m | ||
Related Content
Recent News about Ziarco Pharma
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.